Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold

International Journal of Cardiovascular Imaging

Volumn 28, Issue 6, 2012, Pages 1307-1314

  Brugaletta, Salvatore ^a,b   Gomez Lara, Josep ^a   Garcia Garcia, Hector M ^a,c   Heo, Jung Ho ^a   Farooq, Vasim ^a   Van Geuns, Robert J ^a   Chevalier, Bernard ^d   Windecker, Stephan ^e   McClean, Dougal ^f   Thuesen, Leif ^g   Whitbourn, Robert ^h   Meredith, Ian ⁱ   Dorange, Cecile ^j   Veldhof, Susan ^j   Rapoza, Richard ^j   Ormiston, John A ^k   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL CLÍNIC   (Spain)

^c CARDIALYSIS   (Netherlands)

^d INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^e UNIVERSITY OF BERN   (Switzerland)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

^j ABBOTT VASCULAR   (United States)

^k AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

Bioresorbable vascular scaffold; Coronary plaque; Everolimus; IVUS VH; Necrotic core

Indexed keywords

CALCIUM; EVEROLIMUS; TISSUE SCAFFOLD;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CORONARY STENT; DRUG ELUTING STENT; DRUG IMPLANTATION; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTRAVASCULAR ULTRASOUND; MALE; RATING SCALE; TISSUE NECROSIS; VIRTUAL HISTOLOGY; VIRTUAL REALITY;

ABSORBABLE IMPLANTS; AGED; AUSTRALIA; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; EUROPE; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; NECROSIS; NEW ZEALAND; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; SIROLIMUS; TIME FACTORS; TISSUE SCAFFOLDS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84870407460     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-011-9981-4     Document Type: Article

References (23)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349(14):1315-1323. doi:10.1056/NEJMoa035071 (Pubitemid 37186209)
2. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R (2007) Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27(7):1500-1510. doi:10.1161/ATVBAHA. 107.144220 (Pubitemid 46986103)
3. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48(1):193-202. doi:10.1016/j.jacc.2006.03.042 (Pubitemid 43929240)
4. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R (2009) Comparison of inflammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries. Circulation 120(2):141-149. doi:10.1161/CIRCULATION AHA.107.730010 (141-142)
5. Kubo T, Maehara A, Mintz GS, Garcia-Garcia HM, Serruys PW, Suzuki T, Klauss V, Sumitsuji S, Lerman A, Marso SP, Margolis MP, Margolis JR, Foster MC, De Bruyne B, Leon MB, Stone GW (2010) Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound. Am Heart J 159(2):271-277. doi:10.1016/j.ahj.2009.11.008
6. Kim SW, MintzGS, Hong YJ, Pakala R, ParkKS, PichardAD, Satler LF, KentKM, Suddath WO, Waksman R, Weissman NJ (2008) The virtual histology intravascular ultrasound appearance of newly placed drug-eluting stents. Am J Cardiol 102(9):1182-1186. doi:10.1016/j.amjcard.2008.03.054
7. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D (2009) A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667): 897-910. doi:10.1016/S0140-6736(09)60325-1
8. Sarno G, Onuma Y, Garcia-Garcia HM, Garg S, Regar E, Thuesen L, Dudek D, Veldhof S, Dorange C, Ormiston JA, Serruys PW (2010) IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv 75(6):914-918. doi:10.1002/ ccd.22332
9. Garcia-Garcia HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, Ormiston JA, Regar E, Serruys PW (2009) Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention 4(4):443-448
10. Brugaletta S, Garcia-Garcia HM, Diletti R, Gomez-Lara J, Garg S, Onuma Y, Shin ES, Van Geuns RJ, De Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Dorange C, Veldhof S, Rapoza R, Sudhir K, Bruining N, Ormiston J, Serruys P (2011) Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. Eurointervention 6(9):1110-1116
11. Brugaletta S, Garcia-Garcia HM, Garg S, Gomez-Lara J, Diletti R, Onuma Y, van Geuns RJ, McClean D, Dudek D, Thuesen L, Chevalier B, Windecker S, Whitbourn R, Dorange C, Miquel-Hebert K, Sudhir K, Ormiston JA, Serruys PW (2011) Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging 27(6):859-866. doi:10.1007/s10554-010-9724-y
12. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, De Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith C, Dorange C, Veldhof S, Miquel-Hebert K, Sudhir K, Garcia-Garcia HM, Ormiston JA (2011) Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 58(15):1578-1588
13. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371 (9616):899-907. doi:10.1016/S0140-6736(08)60415-8 (Pubitemid 351384734)
14. Hausmann D, Lundkvist AJ, Friedrich GJ, Mullen WL, Fitzgerald PJ, Yock PG (1994) Intracoronary ultrasound imaging: intraobserver and interobserver variability of morphometric measurements. Am Heart J 128(4):674-680 (Pubitemid 24314653)
15. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG (2002) Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106(17):2200-2206 (Pubitemid 35222213)
16. Garcia-Garcia HM, Mintz GS, Lerman A, Vince DG, Margolis MP, van Es GA, Morel MA, Nair A, Virmani R, Burke AP, Stone GW, Serruys PW (2009) Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention 5(2):177-189
17. Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, van Geuns RJ, Dorange C, Veldhof S, Rapoza R, Whitbourn R, Windecker S, Garcia-Garcia HM, Regar E, Serruys PW (2011) A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 32(3):294-304. doi:10.1093/ eurheartj/ehq458
18. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM (2010) Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122(22): 2301-2312. doi:10.1161/CIRCULATIONAHA.110.970772
19. Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR (2007) Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 49(6): 706-715. doi:10.1016/j.jacc.2006.09.047 (Pubitemid 46205042)
20. Martinet W, Verheye S, De Meyer GR (2007) Everolimusinduced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 3(3): 241-244 (Pubitemid 46752686)
21. Boyle JJ (2005) Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 3(1):63-68 (Pubitemid 40089528)
22. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R (2010) Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122(22):2288-2300. doi: 10.1161/CIRCULATIONAHA.109.921528
23. Hong MK, Park DW, Lee CW, Lee SW, Kim YH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ (2009) Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Interv 2(7):679-688. doi:10.1016/j.jcin.2009. 03.015